DexCom (NASDAQ:DXCM) Announces Earnings Results

DexCom (NASDAQ:DXCM) announced its earnings results on Thursday. The medical device company reported $0.45 earnings per share (EPS) for the quarter, missing the consensus estimate of $0.50 by ($0.05), Zacks reports. DexCom had a net margin of 17.22% and a return on equity of 31.40%.

DexCom Price Performance

NASDAQ:DXCM traded up $0.22 during trading hours on Thursday, hitting $84.09. The stock had a trading volume of 6,770,214 shares, compared to its average volume of 3,442,612. The company has a 50 day simple moving average of $82.11 and a two-hundred day simple moving average of $75.19. The firm has a market capitalization of $32.85 billion, a price-to-earnings ratio of 50.35, a P/E/G ratio of 2.26 and a beta of 1.14. The company has a debt-to-equity ratio of 1.23, a current ratio of 2.46 and a quick ratio of 2.12. DexCom has a one year low of $62.34 and a one year high of $142.00.

Insider Transactions at DexCom

In other news, COO Jacob Steven Leach sold 2,634 shares of DexCom stock in a transaction on Wednesday, January 29th. The shares were sold at an average price of $86.91, for a total transaction of $228,920.94. Following the completion of the sale, the chief operating officer now directly owns 268,644 shares of the company’s stock, valued at approximately $23,347,850.04. The trade was a 0.97 % decrease in their position. The transaction was disclosed in a legal filing with the SEC, which is accessible through this link. Also, EVP Jereme M. Sylvain sold 2,090 shares of the stock in a transaction on Wednesday, January 29th. The shares were sold at an average price of $86.91, for a total value of $181,641.90. Following the completion of the transaction, the executive vice president now directly owns 83,526 shares in the company, valued at approximately $7,259,244.66. This represents a 2.44 % decrease in their position. The disclosure for this sale can be found here. Over the last quarter, insiders have sold 42,342 shares of company stock valued at $3,628,069. 0.30% of the stock is currently owned by company insiders.

Analysts Set New Price Targets

A number of research analysts have weighed in on DXCM shares. Leerink Partners dropped their target price on shares of DexCom from $90.00 to $87.00 and set an “outperform” rating on the stock in a research note on Friday, October 25th. StockNews.com downgraded DexCom from a “buy” rating to a “hold” rating in a research note on Saturday, November 2nd. Sanford C. Bernstein raised their target price on DexCom from $82.00 to $86.00 and gave the stock an “outperform” rating in a research report on Friday, October 25th. Oppenheimer dropped their price target on DexCom from $115.00 to $105.00 and set an “outperform” rating on the stock in a research report on Friday, October 25th. Finally, Redburn Atlantic raised DexCom from a “neutral” rating to a “buy” rating and lifted their price objective for the stock from $85.00 to $115.00 in a report on Monday, February 3rd. Four analysts have rated the stock with a hold rating, thirteen have given a buy rating and two have issued a strong buy rating to the company. According to data from MarketBeat, the company currently has a consensus rating of “Moderate Buy” and a consensus target price of $98.41.

About DexCom

DexCom, Inc, a medical device company, focuses on the design, development, and commercialization of continuous glucose monitoring (CGM) systems in the United States and internationally. The company provides its systems for use by people with diabetes, as well as for use by healthcare providers. Its products include Dexcom G6 and Dexcom G7, integrated CGM systems for diabetes management; Dexcom Share, a remote monitoring system; Dexcom Real-Time API, which enables authorized third-party software developers to integrate real-time CGM data into their digital health apps and devices; and Dexcom ONE, that is designed to replace finger stick blood glucose testing for diabetes treatment decisions.